非小细胞肺癌市场：KOL 洞察

本报告调查非小细胞肺癌市场，并根据美国和欧洲12位关键意见领袖的见解深入探讨了 NSCLC 治疗的演变格局。 Opdivo 和 Keytruda 成为美国和欧洲的标准，调查新辅助和围术期 IO 治疗方案的成长趋势。强调需要更好的预后标记来最佳化基于 IO 的辅助治疗的患者选择。也研究了 Summit 的ivonescimab 作为一种新型治疗方法的潜力，以及基于 mRNA 的疫苗（如 Moderna 的V940）的令人兴奋的前景。

目录

执行摘要

目前与未来的治疗演算法

研究目的

PD-1/L1 为基础的治疗方案

• 核准的治疗方法
  • 晚期非小细胞肺癌 (Merck & Co.; BMS; Roche; AstraZeneca; Regeneron; Daiichi Sankyo)
  • 早期非小细胞肺癌 (Merck & Co.; BMS; Roche; AstraZeneca)
• 最近批准的和研发的处理方法
  • Tevimbra (tislelizumab; BeiGene); Cejemly (sugemalimab; CStone); Zynyz (retifanlimab; Incyte); zimberelimab (Arcus Biosciences)

抗CTLA-4单株抗体

• Gotistobart (BNT316/ONC392; OncoC4/BioNTech)
  • 主要见解摘要

抗LAG3药物

• 研发线疗法
  • Fianlimab (Regeneron); Opdualag (relatlimab + nivolumab; BMS); eftilagimod alpha (IMP321; Immutep)

抗TIGIT单株抗体

• 研发线疗法
  • Tiragolumab (RG6058; Roche); vibostolimab (MK-7684; Merck & Co.); ociperlimab (BGB-A1217; BeiGene); domvanalimab (AB154; Arcus/Gilead); belrestotug (EOS-448; iTeos/GSK)

抗NKG2A/CD73单株抗体

• Monalizumab (IPH2201; AstraZeneca); oleclumab (AstraZeneca)
  • 主要见解摘要

双特异性抗体

• 研发线疗法
  • Ivonescimab (SMT112; Summit)
  • Acasunlimab (GEN1046/BNT311; Genmab)
  • Volrustomig (MEDI5752; AstraZeneca)

新型免疫检查点抑制剂（ICI）

• 研发线疗法
  • Cobolimab (GSK4069889/TSR-022; AnaptysBio/GSK)

IL15受体促效剂

• 研发线疗法
  • Anktiva (N-803/nogapendekin alfa inbakicept; ImmunityBio)

治疗性疫苗

• 研发线疗法
  • V940 (mRNA-4157; Moderna/Merck & Co.); aglatimagene besadenovec (CAN-2409; Candel Therapeutics)

未来治疗趋势

• 主要见解摘要

附录

This report delves into the evolving landscape of NSCLC treatments, focusing on insights from 12 key opinion leaders in the USA and Europe. It explores the growing trend of neoadjuvant and perioperative IO-based regimens, with Opdivo and Keytruda becoming standard in the US and Europe. The report highlights the need for better prognostic markers to refine patient selection for IO-based adjuvant therapy. It also examines the potential of Summit's ivonescimab as a novel therapy and the exciting prospects for mRNA-based vaccines like Moderna's V940. Pharmaceutical professionals will gain a comprehensive understanding of current and future treatment pathways.

Key questions answered:

• What are the preferred IO-based regimens for early-stage, locally advanced, and metastatic NSCLC?
• How has the use of approved immunotherapies evolved, and what are the future trends?
• Which clinical trials of immunotherapies have the potential to significantly impact treatment practice?
• What are the most promising pipeline immune therapies, and how might they affect current market players?
• How is the NSCLC immunotherapy treatment landscape expected to change in the near to medium term?
• What are the key clinical data and trials shaping the current treatment algorithm for NSCLC?

Key brands covered in this report:

List of Companies:

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

PD-1/L1-based regimens

• Approved therapies
  • Advanced NSCLC (Merck & Co.; BMS; Roche; AstraZeneca; Regeneron; Daiichi Sankyo)
  • Early-stage NSCLC (Merck & Co.; BMS; Roche; AstraZeneca)
• Recently approved and pipeline therapies
  • Tevimbra (tislelizumab; BeiGene); Cejemly (sugemalimab; CStone); Zynyz (retifanlimab; Incyte); zimberelimab (Arcus Biosciences)

Anti-CTLA-4 monoclonal antibodies

• Gotistobart (BNT316/ONC392; OncoC4/BioNTech)
  • Key insights summary

Anti-LAG3 agents

• Pipeline therapies
  • Fianlimab (Regeneron); Opdualag (relatlimab + nivolumab; BMS); eftilagimod alpha (IMP321; Immutep)

Anti-TIGIT monoclonal antibodies

• Pipeline therapies
  • Tiragolumab (RG6058; Roche); vibostolimab (MK-7684; Merck & Co.); ociperlimab (BGB-A1217; BeiGene); domvanalimab (AB154; Arcus/Gilead); belrestotug (EOS-448; iTeos/GSK)

Anti-NKG2A/CD73 monoclonal antibodies

• Monalizumab (IPH2201; AstraZeneca); oleclumab (AstraZeneca)
  • Key insights summary

Bispecific antibodies

• Pipeline therapies
  • Ivonescimab (SMT112; Summit)
  • Acasunlimab (GEN1046/BNT311; Genmab)
  • Volrustomig (MEDI5752; AstraZeneca)

Novel immune checkpoint inhibitors (ICIs)

• Pipeline therapies
  • Cobolimab (GSK4069889/TSR-022; AnaptysBio/GSK)

IL15 receptor agonists

• Pipeline therapies
  • Anktiva (N-803/nogapendekin alfa inbakicept; ImmunityBio)

Therapeutic vaccines

• Pipeline therapies
  • V940 (mRNA-4157; Moderna/Merck & Co.); aglatimagene besadenovec (CAN-2409; Candel Therapeutics)

Future treatment trends

• Key insights summary

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe